Ona Therapeutics, an innovative biopharmaceutical company dedicated to redefining the landscape of cancer treatment, has successfully raised $35 million in a recent funding round. This significant investment underscores the trust and confidence that investors have in Ona’s pioneering approach to developing first-in-class antibody drug conjugates (ADCs). The funds will be strategically allocated to expedite ongoing research and development efforts aimed at discovering novel therapeutic targets uniquely derived from the molecular characteristics of advanced cancer patients who have exhausted all standard treatment options. By forging partnerships with leading academics and clinicians, Ona Therapeutics is positioned to leverage cutting-edge scientific insights and technology, translating them into effective therapies for this underserved patient population. With the combination of privileged biological knowledge and its expertise in biologics, Ona is crafting ADCs and antibody therapies that hold the potential to provide life-changing treatment alternatives. The ultimate goal is to tackle the complex challenges presented by advanced cancer, offering hope and improved outcomes for individuals facing the dire circumstances of treatment-resistant disease. This funding not only accelerates Ona’s commitment to innovation in cancer therapeutics but also represents a critical step forward in the quest for effective and meaningful treatments that can make a significant difference in the lives of patients in need. As the company moves forward, its vision to revolutionize cancer care is more tangible than ever, promising a brighter future for those battling advanced cancers.
Ona Therapeutics Secures $35 Million in Series A Funding to Advance Revolutionary Cancer Treatments
Recently funded · $35.0M Series aHealthcare
Get the full Ona Therapeutics company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
Other recent Series a rounds
Companies that recently closed a Series a round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Aligned Marketplace | Series a | $20.0M | today |
| 2 |  Vals AI United States | Series a | $40.0M | today |
| 3 |
.png&w=3840&q=75)
